Kieltyka Kasia, McAuliffe Brian, Cianci Christopher, Drexler Dieter M, Shou Wilson, Zhang Jun
Discovery Chemistry Platforms, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492.
Discovery Infectious Diseases, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492.
J Pharm Sci. 2016 Mar;105(3):1036-42. doi: 10.1016/S0022-3549(15)00177-X. Epub 2016 Jan 27.
Membrane-based devices typically used for serum protein binding determination are not fully applicable to highly lipophilic compounds because of nonspecific binding to the device membrane. Ultracentrifugation, however, completely eliminates the issue by using a membrane-free approach, although its wide application has been limited. This lack of utilization is mainly attributed to 2 factors: the high cost in acquiring and handling of radiolabeled compounds and low assay throughput owing to the difficulties in process automation. To overcome these challenges, we report a high-throughput workflow by cassette ultracentrifugation of nonradiolabeled compounds followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Twenty compounds with diverse physicochemical and protein binding properties were selected for the evaluation of the workflow. To streamline the working process, approaches of matrix balancing for all the samples for LC-MS/MS analysis and determining free fraction without analytical calibration curves were adopted. Both the discrete ultracentrifugation of individual compounds and cassette ultracentrifugation of all the test compounds followed by simultaneous LC-MS/MS analysis exhibited a linear correlation with literature values, demonstrating respectively the validity of the ultracentrifugation process and the cassette approach. The cassette ultracentrifugation using nonradiolabeled compounds followed by LC-MS/MS analysis has greatly facilitated its application for high-throughput protein binding screening in drug discovery.
基于膜的装置通常用于血清蛋白结合测定,但由于与装置膜的非特异性结合,并不完全适用于高亲脂性化合物。然而,超速离心通过采用无膜方法完全消除了这个问题,尽管其广泛应用受到限制。这种应用不足主要归因于两个因素:获取和处理放射性标记化合物的成本高,以及由于过程自动化困难导致的分析通量低。为了克服这些挑战,我们报告了一种高通量工作流程,通过对非放射性标记化合物进行盒式超速离心,然后进行液相色谱-串联质谱(LC-MS/MS)分析。选择了20种具有不同物理化学和蛋白结合特性的化合物来评估该工作流程。为了简化工作过程,采用了对所有用于LC-MS/MS分析的样品进行基质平衡以及无需分析校准曲线即可确定游离分数的方法。对单个化合物的离散超速离心以及对所有测试化合物进行盒式超速离心然后同时进行LC-MS/MS分析,均与文献值呈线性相关,分别证明了超速离心过程和盒式方法的有效性。使用非放射性标记化合物进行盒式超速离心然后进行LC-MS/MS分析,极大地促进了其在药物发现中高通量蛋白结合筛选的应用。